The HemOnc Pulse

Dr. Omar Nadeem, a Senior Physician at Dana-Farber and Assistant Professor at Harvard, shares cutting-edge developments in smoldering myeloma. He discusses how genomic profiling can refine risk stratification and highlight high-risk patients, allowing for personalized treatment. The role of innovative models like PANGEA and AI in dynamic risk assessment is explored, alongside exciting insights into bispecific antibodies and their early successes in trials. Dr. Nadeem emphasizes the shift towards early detection and intervention strategies to improve patient outcomes.

Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.

Dr. Gabriela Hobbs, a leading hematologist and MPN researcher at Massachusetts General Hospital, shares groundbreaking insights on myeloproliferative neoplasms. She delves into the impressive results from the VERIFY trial on rusfertide, detailing its hematocrit control and safety profile. Dr. Hobbs also discusses the efficacy of ropeginterferon and its advantages over traditional treatments. Additionally, she highlights ongoing clinical trials to watch and emphasizes the pressing need for therapies addressing thrombocytopenia and disease progression.

Host Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.

MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.

William Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today Managing Editor, Nichole Tucker.

In this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.

A panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigms.

Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.

During a session at The HemOnc Pulse Live! moderated by Naval Daver, MD, Eunice Wang, MD presents new insights in acute myeloid leukemia care, joined by Aditi Shastri, MBBS, Tapan Kadiya, MD, and Kelly Chien, MD for a rich panel on mutation loss, minimal residual disease, and transplant timing.